PathAI Diagnostics’ Post

#ICYMI PathAI announced a new multifaceted #partnership with Quest Diagnostics designed to accelerate the adoption of digital and #AI #pathology innovations. https://lnkd.in/e8ES2-mA PathAI continues to operate as an independent entity, offering our services and capabilities to more partners and customers with more flexibility than before.    Here are the key takeaways: 1) Licensing of PathAI’s AISight™ IMS and Algorithm Portfolio  - Quest will license and deploy PathAI's AISight™ #digitalpathology image management system and algorithm portfolio to support their pathology laboratories across the USA. - Significant milestone in the adoption of digital pathology and AI. - Proof of the quality and value of our #data, #development, and #distribution capabilities.   2) Acquisition of PathAI Diagnostics (formerly Poplar Healthcare)  - Quest Diagnostics will acquire select assets of PathAI’s clinical anatomic pathology laboratory business, PathAI Diagnostics (formerly Poplar Healthcare) - PathAI transformed this lab over the past 3 years into a state-of-the-art digitized lab that will serve as Quest’s AI and digital R&D and solutions center. - PathAI will continue to operate as an independent entity, developing digital pathology and AI-powered tools for pathology laboratories and to advance drug development for #biopharma.   3) PathAI Selects Quest as a Preferred Partner for Biopharma Lab Business - PathAI may explore opportunities for mutual support and collaboration in algorithm product menu and IMS evolution. - Product and service enhancements will support all PathAI customers.   PathAI remains committed to accelerating the shift to digital & AI for pathology laboratories and biopharma’s shift towards digitalization.